PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.81%
Revenue growth at 50-75% of MRVL's 11.40%. Martin Whitman would worry about competitiveness or product relevance.
6.60%
Gross profit growth at 50-75% of MRVL's 12.16%. Martin Whitman would question if cost structure or brand is lagging.
5.91%
Positive EBIT growth while MRVL is negative. John Neff might see a substantial edge in operational management.
5.91%
Positive operating income growth while MRVL is negative. John Neff might view this as a competitive edge in operations.
9.05%
Net income growth under 50% of MRVL's 120.09%. Michael Burry would suspect the firm is falling well behind a key competitor.
9.09%
EPS growth under 50% of MRVL's 120.18%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
26.32%
Diluted EPS growth under 50% of MRVL's 120.18%. Michael Burry would worry about an eroding competitive position or excessive dilution.
No Data
No Data available this quarter, please select a different quarter.
-9.46%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-33.58%
Negative OCF growth while MRVL is at 562.36%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-44.88%
Negative FCF growth while MRVL is at 2269.09%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
660.55%
Similar 10Y revenue/share CAGR to MRVL's 727.27%. Walter Schloss might see both firms benefiting from the same long-term demand.
132.27%
5Y revenue/share CAGR under 50% of MRVL's 352.44%. Michael Burry would suspect a significant competitive gap or product weakness.
103.68%
3Y revenue/share CAGR at 75-90% of MRVL's 126.82%. Bill Ackman would expect new product strategies to close the gap.
3767.77%
10Y OCF/share CAGR 1.25-1.5x MRVL's 3151.63%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
83.91%
Below 50% of MRVL's 678.59%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
144.23%
3Y OCF/share CAGR 1.25-1.5x MRVL's 120.18%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
1329.20%
Net income/share CAGR above 1.5x MRVL's 100.24% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
356.93%
5Y net income/share CAGR above 1.5x MRVL's 104.31%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
413.54%
Positive short-term CAGR while MRVL is negative. John Neff would see a clear advantage in near-term profit trajectory.
1605.93%
Positive growth while MRVL is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
154.20%
5Y equity/share CAGR above 1.5x MRVL's 41.35%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
113.15%
3Y equity/share CAGR above 1.5x MRVL's 24.81%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.65%
Our AR growth while MRVL is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
17.11%
Inventory growth well above MRVL's 9.96%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
7.84%
Asset growth above 1.5x MRVL's 1.82%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
5.65%
BV/share growth above 1.5x MRVL's 3.26%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
9.08%
R&D growth drastically higher vs. MRVL's 5.65%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
3.49%
SG&A declining or stable vs. MRVL's 37.85%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.